World Athletics has officially introduced a new genetic testing policy for athletes who want to compete in the female category at international track and field competitions. Starting September 1, all such athletes must undergo a one-time SRY gene test—using either a cheek swab or a blood sample—to verify their biological sex.
The decision follows past controversies, including the 2023 disqualification of Algerian boxer Imane Khelif due to an undisclosed gender eligibility test result. Although she was later cleared to participate in the 2024 Olympics, with the committee upholding her right to compete without discrimination, the incident sparked broader debate.
According to a July 30 statement from World Athletics, the new SRY test is seen as a reliable method for determining biological sex. President Sebastian Coe emphasized that the primary goal is to preserve the integrity and fairness of women’s athletics, ensuring that female athletes compete on a level playing field.
Under the new guidelines, eligibility for the female category is limited to biological females, individuals assigned male at birth who never went through male puberty, and athletes with differences in sex development who meet specific transitional criteria. However, transgender women are excluded from these provisions, as none currently compete at the elite international level under existing rules.
Additionally, any biological female who has used testosterone as part of gender transition treatment must wait a specified period after ceasing testosterone use—per anti-doping regulations—before they can compete in the female category. World Athletics thanked its Member Federations for supporting the implementation of these updated policies.